keyword
MENU ▼
Read by QxMD icon Read
search

major depressive disorder biomarkers

keyword
https://www.readbyqxmd.com/read/29225582/significant-need-for-a-french-network-of-expert-centers-enabling-a-better-characterization-and-management-of-treatment-resistant-depression-fondation-fondamental
#1
Antoine Yrondi, Djamila Bennabi, Emmanuel Haffen, Marion Garnier, Frank Bellivier, Thierry Bourgerol, Vincent Camus, Thierry D'Amato, Olivier Doumy, Frédéric Haesebaert, Jérôme Holtzmann, Christophe Lançon, Philippe Vignaud, Fanny Moliere, Isabel Nieto, Raphaëlle Marie Richieri, Philippe Domenech, Corentin Rabu, Luc Mallet, Liova Yon, Laurent Schmitt, Florian Stephan, Guillaume Vaiva, Michel Walter, Pierre-Michel Llorca, Philippe Courtet, Marion Leboyer, Wissam El-Hage, Bruno Aouizerate
Background: Major depression is characterized by (i) a high lifetime prevalence of 16-17% in the general population; (ii) a high frequency of treatment resistance in around 20-30% of cases; (iii) a recurrent or chronic course; (iv) a negative impact on the general functioning and quality of life; and (v) a high level of comorbidity with various psychiatric and non-psychiatric disorders, high occurrence of completed suicide, significant burden along with the personal, societal, and economic costs...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29224411/change-in-quantitative-eeg-theta-cordance-as-a-potential-predictor-of-repetitive-transcranial-magnetic-stimulation-clinical-outcome-in-major-depressive-disorder
#2
Aimee M Hunter, Thien X Nghiem, Ian A Cook, David E Krantz, Michael J Minzenberg, Andrew F Leuchter
Repetitive transcranial magnetic stimulation (rTMS) has demonstrated efficacy in major depressive disorder (MDD), although clinical outcome is variable. Change in the resting-state quantitative electroencephalogram (qEEG), particularly in theta cordance early in the course of treatment, has been linked to antidepressant medication outcomes but has not been examined extensively in clinical rTMS. This study examined change in theta cordance over the first week of clinical rTMS and sought to identify a biomarker that would predict outcome at the end of 6 weeks of treatment...
November 1, 2017: Clinical EEG and Neuroscience: Official Journal of the EEG and Clinical Neuroscience Society (ENCS)
https://www.readbyqxmd.com/read/29217258/predictive-brain-networks-for-major-depression-in-a-semi-multimodal-fusion-hierarchical-feature-reduction-framework
#3
Jie Yang, Yingying Yin, Zuping Zhang, Jun Long, Jian Dong, Yuqun Zhang, Zhi Xu, Lei Li, Jie Liu, Yonggui Yuan
Major depressive disorder (MDD) is characterized by dysregulation of distributed structural and functional networks. It is now recognized that structural and functional networks are related at multiple temporal scales. The recent emergence of multimodal fusion methods has made it possible to comprehensively and systematically investigate brain networks and thereby provide essential information for influencing disease diagnosis and prognosis. However, such investigations are hampered by the inconsistent dimensionality features between structural and functional networks...
December 5, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/29209581/methylenetetrahydrofolate-reductase-a1298c-polymorphism-and-major-depressive-disorder
#4
REVIEW
Kevin Cho, Zubair M Amin, Jie An, Kerry Anne Rambaran, Tyler B Johnson, Saeed K Alzghari
Major depressive disorder (MDD) is a disorder that carries significant psychosocial and economic implications. Research efforts have focused on identifying biomarkers that can aid in the prediction, diagnosis, and efficacious treatment of MDD. Most of this focus has been placed on a polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene, C677T. MTHFR C677T is screened during MDD diagnosis in many protocols. However, MTHFR C667T poses conflicting data in various ethnic groups and geographic populations calling into question its utility...
October 1, 2017: Curēus
https://www.readbyqxmd.com/read/29181274/assessment-of-brain-functional-connectome-alternations-and-correlation-with-depression-and-anxiety-in-major-depressive-disorders
#5
Vincent Chin-Hung Chen, Chao-Yu Shen, Sophie Hsin-Yi Liang, Zhen-Hui Li, Ming-Hong Hsieh, Yeu-Sheng Tyan, Mong-Liang Lu, Yena Lee, Roger S McIntyre, Jun-Cheng Weng
Major depressive disorder (MDD) is highly prevalent, recurrent, and associated with functional impairment, morbidity, and mortality. Herein, we aimed to identify disruptions in functional connectomics among subjects with MDD by using resting-state functional magnetic resonance imaging (rs-fMRI). Sixteen subjects with MDD and thirty health controls completed resting-state fMRI scans and clinical assessments (e.g., Hamilton Depression Rating Scale (HAMD) and Hospital Anxiety and Depression Scale (HADS)). We found higher amplitude of low frequency fluctuations (ALFF) bilaterally in the hippocampus and amygdala among MDD subjects when compared to healthy controls...
2017: PeerJ
https://www.readbyqxmd.com/read/29179585/immune-based-strategies-for-mood-disorders-facts-and-challenges
#6
Gabriela D Colpo, Marion Leboyer, Robert Dantzer, Mahdukar H Trivedi, Antonio L Teixeira
Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions...
November 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/29174766/brain-choline-in-major-depression-a-review-of-the-literature
#7
Colin A Riley, Perry F Renshaw
The focus of this review is to provide a synthesis of the current literature on the role of brain choline, as measured by proton magnetic resonance spectroscopy (1H-MRS), in major depressive disorder (MDD). The most recent 1H-MRS literature review took place over 10 years ago and, reflecting the high level of research on this topic, much has been learned since then. Higher brain choline levels have been linked to an increase in depression, and a cholinergic model for MDD development has been postulated. However, current 1H-MRS studies have been inconclusive regarding the role of choline in depression...
November 20, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/29173175/imaging-the-role-of-inflammation-in-mood-and-anxiety-related-disorders
#8
Jennifer C Felger
BACKGROUND: Studies investigating the impact of a variety of inflammatory stimuli on the brain and behavior have reported evidence that inflammation and release of inflammatory cytokines affect circuitry relevant to both reward and threat sensitivity to contribute to behavioral change. Of relevance to mood and anxiety-related disorders, biomarkers of inflammation such as inflammatory cytokines and acute-phase proteins are reliably elevated in a significant proportion of patients with major depressive disorder (MDD), bipolar disorder, anxiety disorders and post-traumatic stress disorder (PTSD)...
November 23, 2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/29169123/the-comparative-effectiveness-of-electroencephalographic-indices-in-predicting-response-to-escitalopram-therapy-in-depression-a-pilot-study
#9
Anusha Baskaran, Faranak Farzan, Roumen Milev, Colleen A Brenner, Sravya Alturi, Mary Pat McAndrews, Pierre Blier, Ken Evans, Jane A Foster, Benicio N Frey, Peter Giacobbe, Raymond W Lam, Francesco Leri, Glenda M MacQueen, Daniel J Müller, Sagar V Parikh, Susan Rotzinger, Claudio N Soares, Steven C Strother, Gustavo Turecki, Sidney H Kennedy
BACKGROUND: This study aims to compare the effectiveness of EEG frequency band activity including interhemispheric asymmetry and prefrontal theta cordance in predicting response to escitalopram therapy at 8-weeks post-treatment, in a multi-site initiative. METHODS: Resting state 64-channel EEG data were recorded from 44 patients with a diagnosis of major depressive disorder (MDD) as part of a larger, multisite discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND)...
November 3, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29163018/brain-networks-implicated-in-seasonal-affective-disorder-a-neuroimaging-pet-study-of-the-serotonin-transporter
#10
Martin Nørgaard, Melanie Ganz, Claus Svarer, Patrick M Fisher, Nathan W Churchill, Vincent Beliveau, Cheryl Grady, Stephen C Strother, Gitte M Knudsen
Background: Seasonal Affective Disorder (SAD) is a subtype of Major Depressive Disorder characterized by seasonally occurring depression that often presents with atypical vegetative symptoms such as hypersomnia and carbohydrate craving. It has recently been shown that unlike healthy people, patients with SAD fail to globally downregulate their cerebral serotonin transporter (5-HTT) in winter, and that this effect seemed to be particularly pronounced in female S-carriers of the 5-HTTLPR genotype. The purpose of this study was to identify a 5-HTT brain network that accounts for the adaption to the environmental stressor of winter in females with the short 5-HTTLPR genotype, a specific subgroup previously reported to be at increased risk for developing SAD...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29150145/neuroimaging-biomarkers-as-predictors-of-treatment-outcome-in-major-depressive-disorder
#11
REVIEW
Trehani M Fonseka, Glenda M MacQueen, Sidney H Kennedy
BACKGROUND: Current practice for selecting pharmacological and non-pharmacological antidepressant treatments has yielded low response and remission rates in Major Depressive Disorder (MDD). Neuroimaging biomarkers of brain structure and function may be useful in guiding treatment selection by predicting response vs. non-response outcomes. METHODS: In this review, we summarize data from studies examining predictors of treatment response using structural and functional neuroimaging modalities, as they pertain to pharmacotherapy, psychotherapy, and stimulation treatment strategies...
October 31, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29137178/antidepressants-and-mood-stabilizers-novel-research-avenues-and-clinical-insights-for-bipolar-depression
#12
REVIEW
In Hee Shim, Young Sup Woo, Moon-Doo Kim, Won-Myong Bahk
The concept of the bipolar-spectrum and of mixed features being a bridge between major depressive disorders and bipolar disorders (BDs) has become increasingly important in mood-disorder diagnoses. Under these circumstances, antidepressants (ADs) and mood stabilizers (MSs) should be used with caution in the treatment of major depressive episodes (MDEs) and to obtain long-term stability in BDs. Before treating MDEs, screening tools, specific symptom evaluation and medical history should be used to distinguish between bipolarity and mixed features in patients for whom AD monotherapy may present a risk...
November 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29133948/increased-hippocampal-tail-volume-predicts-depression-status-and-remission-to-anti-depressant-medications-in-major-depression
#13
J J Maller, K Broadhouse, A J Rush, E Gordon, S Koslow, S M Grieve
Studies of patients with major depressive disorder (MDD) have consistently reported reduced hippocampal volumes; however, the exact pattern of these volume changes in specific anatomical subfields and their functional significance is unclear. We sought to clarify the relationship between hippocampal tail volumes and (i) a diagnosis of MDD, and (ii) clinical remission to anti-depressant medications (ADMs). Outpatients with nonpsychotic MDD (n=202) based on DSM-IV criteria and a 17-item Hamilton Rating Scale for Depression (HRSD17) score ⩾16 underwent pretreatment magnetic resonance imaging as part of the international Study to Predict Optimized Treatment for Depression (iSPOT-D)...
November 14, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/29082433/reproductive-affective-disorders-a-review-of-the-genetic-evidence-for-premenstrual-dysphoric-disorder-and-postpartum-depression
#14
REVIEW
Katherine McEvoy, Lauren M Osborne, Julie Nanavati, Jennifer L Payne
PURPOSE OF REVIEW: The purpose of this study is to review and summarize the literature exploring the genetic basis for premenstrual dysphoric disorder (PMDD) and postpartum depression (PPD). RECENT FINDINGS: There is more evidence for a genetic basis for PPD than for PMDD, but only when PPD is defined as beginning in the immediate postpartum time period. Familial, genome-wide linkage and association studies, and candidate gene studies, most in the past 10 years, have examined the genetic etiology of reproductive affective disorders, including PMDD and PPD...
October 30, 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29076894/the-potential-of-predictive-analytics-to-provide-clinical-decision-support-in-depression-treatment-planning
#15
Ronald C Kessler
PURPOSE OF REVIEW: To review progress developing clinical decision support tools for personalized treatment of major depressive disorder (MDD). RECENT FINDINGS: Over the years, a variety of individual indicators ranging from biomarkers to clinical observations and self-report scales have been used to predict various aspects of differential MDD treatment response. Most of this work focused on predicting remission either with antidepressant medications versus psychotherapy, some antidepressant medications versus others, some psychotherapies versus others, and combination therapies versus monotherapies...
October 25, 2017: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/29076893/major-depression-and-its-treatment-micrornas-as-peripheral-biomarkers-of-diagnosis-and-treatment-response
#16
Juan P Lopez, Aron Kos, Gustavo Turecki
PURPOSE OF REVIEW: Major depressive disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Despite its considerable burden, our understanding of its pathophysiology remains rudimentary, and a validated biomarker has yet to be identified. Antidepressants are the most common treatment for MDD, yet roughly one-third of patients experience an inadequate response. Thus, there is a great need for not only identifying biomarkers of MDD but also those that can predict and monitor or just monitor response to treatment...
October 25, 2017: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/29070016/investigating-the-epigenetic-profile-of-the-inflammatory-gene-il-6-in-late-life-depression
#17
Joanne Ryan, Lauren Pilkington, Katharina Neuhaus, Karen Ritchie, Marie-Laure Ancelin, Richard Saffery
BACKGROUND: It is well established that there is a link between inflammation and depression, with several studies reporting increased circulating levels of the pro-inflammatory cytokine, interleukin-6 (IL6), in depressed individuals. Peripheral epigenetic marks, including DNA methylation, hold promise as biomarkers for a range of complex conditions, with potential to inform diagnosis and tailor interventions. The aim of this study was to determine whether individuals with depression display differential methylation of the IL6 gene promoter compared to individuals without depression...
October 25, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29060118/simple-and-objective-screening-of-major-depressive-disorder-by-heart-rate-variability-analysis-during-paced-respiration-and-mental-task-conditions
#18
Mai Kobayashi, Guanghao Sun, Toshikazu Shinba, Takemi Matsui, Tetsuo Kirimoto
Since objective biomarkers for major depressive disorder (MDD) are not readily available, clinical psychiatrists diagnose patients with MDD subjectively based on clinical interviews and diagnostic criteria. It often raises various concerns, including false responses by patients, subjective factors, and inexperience of the attendants leading to incorrect diagnosis. Here, we developed a self-monitoring system for simple and objective screening of MDD using a photoplethysmography (PPG) sensor and a 24-GHz microwave radar, which was based on the analysis of heart rate variability (HRV) during paced respiration and mental task conditions...
July 2017: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/29057665/medications-for-substance-use-disorders-sud-emerging-approaches
#19
Eduardo R Butelman, Mary Jeanne Kreek
Substance use disorders are a group of chronic relapsing disorders of the brain, which have massive public health and societal impact. In some disorders (e.g., heroin/prescription opioid addictions) approved medications have a major long-term benefit. For other substances (e.g., cocaine, amphetamines and cannabis) there are no approved medications, and for alcohol there are approved treatments, which are not in wide usage. Approved treatments for tobacco use disorders are available, and novel medications are also under study...
October 30, 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29042527/-biomarkers-for-mood-disorders-and-a-novel-antidepressant-r-ketamine
#20
Kenji Hashimoto
Depression is often misdiagnosed as major depressive disorder in patients with bipolar disorder. Therapeutic drugs for these two disorders are quite different, but the anesthetic ketamine shows fast-acting antidepressant effects in treatment-resistant patients with these disorders. Here, we discuss biomarkers for both disorders, recent findings regarding ketamine, and predictable biomarkers for ketamine's antidepressant actions.
October 2017: Brain and Nerve, Shinkei Kenkyū No Shinpo
keyword
keyword
106962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"